相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1995
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- Orbus Therapeutics will present updated Phase 3 STELLAR trial results showing eflornithine improves overall survival and progression-free survival in patients with recurrent WHO 2021 grade 3 IDH-mutant astrocytoma. - Eflornithine is a novel cytostatic agent that irreversibly inhibits ornithine decarboxylase, a key enzyme in polyamine biosynthesis that is upregulated in certain cancers. - The drug has received FDA Orphan Drug Designation and Breakthrough Therapy Designation for anaplastic glioma treatment, along with European Medicines Agency Orphan Medicinal Product status. - Results will be presented at the Society for Neuro-Oncology Annual Meeting by Dr. Howard Colman from the Huntsman Cancer Institute at the University of Utah.
- Quanta Therapeutics will present Phase 1 clinical data for QTX3034, an oral G12D-preferring multi-KRAS inhibitor, at the 2025 AACR-NCI-EORTC International Conference on October 24, 2025. - The ongoing Phase 1 trial evaluates QTX3034 as monotherapy and in combination with cetuximab in patients with KRASG12D mutant solid tumors. - Dose expansion cohorts are enrolling patients with KRASG12D-mutant pancreatic, colorectal, and endometrial cancers to assess safety, tolerability, and preliminary efficacy. - Quanta's unique platform uses Second Harmonic Generation optical technology to identify allosteric modulators targeting protein-protein interactions key to oncogenic RAS activity.
- The Phase 3 AMPLITUDE trial published in Nature Medicine demonstrates clinical benefit of combining niraparib with abiraterone acetate plus prednisone in patients with metastatic hormone-sensitive prostate cancer harboring HRR gene alterations. - The targeted triplet therapy significantly improved radiographic progression-free survival, with hazard ratios of 0.52 for BRCA1/2 patients and 0.63 for the intention-to-treat population. - This landmark study represents the first targeted triplet therapy to show benefit for HRR-deficient tumors in the hormone-sensitive disease stage, making a strong case for upfront genomic sequencing.
- Ryght AI announces formation of inaugural Scientific Advisory Board comprising 12 globally recognized experts in oncology, hematology, dermatology, and AI to guide clinical trial innovation. - The board will oversee development of AI Site Twin technology, which creates dynamic digital replicas of research facilities to transform site selection and trial operations. - Advisory board members emphasize the platform's potential to accelerate patient recruitment and streamline workflows, bringing therapies to market months or years ahead of schedule. - The technology addresses longstanding challenges in clinical trial feasibility by replacing static, outdated data with real-time insights powered by generative AI.
- Repertoire Immune Medicines has appointed Robert Andtbacka, MD, as Chief Medical Officer to strengthen leadership as the company prepares for its first clinical trial. - The company's lead candidate RPTR-1-201, a TCR bispecific targeting novel peptides on solid tumors, is progressing through IND-enabling studies following positive regulatory interactions. - RPTR-1-201 represents Repertoire's first clinical-stage asset discovered using their proprietary DECODE platform, with plans to initiate Phase 1/2 trials across multiple cancer indications. - Dr. Andtbacka brings over 20 years of oncology drug development experience from roles at HiFiBiO Therapeutics, Seven and Eight Biopharmaceuticals, and Huntsman Cancer Institute.
- Huntsman Cancer Institute at the University of Utah has achieved the first-ever allogeneic stem cell transplant using cells from a deceased donor, potentially revolutionizing treatment access for blood cancer patients. - The innovative approach harvests stem cells from the vertebral column of deceased organ donors, creating a bank of frozen stem cells that could eliminate lengthy donor searches and matching delays. - This Phase 1 clinical trial (NCT05589896) aims to provide timely transplant options for patients with aggressive blood cancers like acute myeloid leukemia and non-Hodgkin lymphoma, especially benefiting those without matching living donors.
- Researchers have identified a promising combination therapy using FAK inhibitors with RAF-MEK clamps that effectively overcomes treatment resistance in BRAF V600E-mutated melanoma. - The dual-targeting approach not only treats existing brain metastases but also prevents melanoma cells from spreading to the brain, addressing a critical unmet need for patients with limited treatment options. - This oral combination therapy of defactinib (FAK inhibitor) and avutometinib (RAF-MEK inhibitor) could improve accessibility for melanoma patients in rural areas who struggle to access infusion-based immunotherapies.
• IMPLEMENT sub-analysis shows significant disparities in treatment intensification practices between academic and non-academic physicians treating metastatic castration-sensitive prostate cancer. • Non-academic physicians report more barriers including knowledge gaps and side effect concerns, while academic physicians emphasize clinical support and survival benefits as key drivers. • Study highlights need for targeted educational interventions and patient advocacy to bridge treatment adoption gap in prostate cancer care.
- The combination of talazoparib and enzalutamide demonstrated an 8.8-month improvement in overall survival compared to enzalutamide alone in metastatic castration-resistant prostate cancer patients. - Patients with homologous recombination repair-deficient tumors showed an even more pronounced benefit, with a 14-month survival improvement and 38% reduction in death risk. - The phase 3 TALAPRO-2 trial revealed manageable safety profiles with no new concerns, despite grade 3/4 anemia occurring in 49% of patients, which was effectively managed through dose adjustments.
- A randomized clinical trial led by Huntsman Cancer Institute demonstrates that two sessions of high-dose vaginal brachytherapy are as effective as standard multiple low-dose treatments for endometrial cancer. - The SAVE trial findings offer a more convenient treatment option for patients, particularly benefiting those in rural areas who face challenges accessing multiple treatment sessions. - Research shows comparable short-term outcomes and minimal acute toxicities between the new two-session approach and traditional 3-5 session treatment protocol.
